The Cooper Cos. (NYSE:COO) saw unusually-strong trading volume on Wednesday . Approximately 698,480 shares were traded during mid-day trading, an increase of 75% from the previous session’s volume of 400,114 shares.The stock last traded at $185.45 and had previously closed at $186.41.

A number of equities research analysts have recently issued reports on COO shares. Jefferies Group increased their price target on shares of The Cooper Cos. from $190.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, August 24th. Stifel Nicolaus lifted their price target on shares of The Cooper Cos. from $180.00 to $195.00 and gave the company a “buy” rating in a report on Thursday, June 30th. Robert W. Baird lifted their price target on shares of The Cooper Cos. from $185.00 to $196.00 and gave the company an “outperform” rating in a report on Thursday, August 18th. Stephens reiterated a “hold” rating on shares of The Cooper Cos. in a report on Saturday, June 4th. Finally, JPMorgan Chase & Co. initiated coverage on shares of The Cooper Cos. in a report on Wednesday, July 13th. They issued a “buy” rating on the stock. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The Cooper Cos. currently has a consensus rating of “Buy” and a consensus target price of $177.70.

The stock has a 50-day moving average of $184.60 and a 200-day moving average of $167.89. The company has a market capitalization of $9.07 billion, a PE ratio of 36.46 and a beta of 0.20.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/the-cooper-cos-coo-sees-strong-trading-volume.html

The Cooper Cos. (NYSE:COO) last released its quarterly earnings results on Thursday, September 1st. The medical device company reported $2.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.29 by $0.01. The Cooper Cos. had a return on equity of 14.89% and a net margin of 13.14%. The company had revenue of $514.70 million for the quarter. During the same quarter in the previous year, the company posted $1.97 EPS. The business’s quarterly revenue was up 11.5% on a year-over-year basis. On average, equities research analysts expect that The Cooper Cos. will post $8.43 earnings per share for the current year.

In other The Cooper Cos. news, Director William A. Kozy acquired 270 shares of the business’s stock in a transaction on Tuesday, September 6th. The shares were bought at an average price of $186.69 per share, with a total value of $50,406.30. Following the transaction, the director now directly owns 770 shares of the company’s stock, valued at approximately $143,751.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert S. Weiss sold 151,839 shares of the company’s stock in a transaction on Monday, June 27th. The shares were sold at an average price of $163.02, for a total value of $24,752,793.78. Following the completion of the transaction, the chief executive officer now directly owns 200,617 shares in the company, valued at approximately $32,704,583.34. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.

A number of institutional investors have recently made changes to their positions in COO. Vanguard Group Inc. increased its position in shares of The Cooper Cos. by 2.8% in the second quarter. Vanguard Group Inc. now owns 3,644,352 shares of the medical device company’s stock valued at $625,262,000 after buying an additional 100,238 shares during the period. BlackRock Fund Advisors increased its position in shares of The Cooper Cos. by 4.7% in the second quarter. BlackRock Fund Advisors now owns 1,709,402 shares of the medical device company’s stock valued at $293,282,000 after buying an additional 75,993 shares during the period. State Street Corp increased its position in shares of The Cooper Cos. by 0.5% in the second quarter. State Street Corp now owns 1,557,106 shares of the medical device company’s stock valued at $267,142,000 after buying an additional 8,276 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of The Cooper Cos. by 3.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,472,668 shares of the medical device company’s stock valued at $252,666,000 after buying an additional 44,626 shares during the period. Finally, Westfield Capital Management Co. LP increased its position in shares of The Cooper Cos. by 6.6% in the second quarter. Westfield Capital Management Co. LP now owns 785,363 shares of the medical device company’s stock valued at $134,745,000 after buying an additional 48,718 shares during the period. 98.67% of the stock is currently owned by institutional investors.

About The Cooper Cos.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

5 Day Chart for NYSE:COO

Receive News & Ratings for The Cooper Cos. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Cos. and related companies with MarketBeat.com's FREE daily email newsletter.